Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

93.53
+2.963.27%
Pre-market: 93.950.4200+0.45%09:24 EDT
Volume:889.30K
Turnover:83.43M
Market Cap:4.56B
PE:-21.64
High:95.46
Open:91.39
Low:90.51
Close:90.57
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:1.04
T/O Rate:2.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-356.87
PE(LYR):-24.68

Loading ...

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)

TIPRANKS
·
May 15

Celcuity Q1 FY26 net loss widens 43% to $52.84 million

Reuters
·
May 15

Celcuity Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

Notable companies reporting after market close

TIPRANKS
·
May 15

Biotech firm Celcuity reports smaller-than-expected Q1 loss

Reuters
·
May 15

Celcuity Q1 Adjusted Loss Widens

MT Newswires Live
·
May 15

Celcuity Q1 Adj. EPS $(0.86) Beats $(1.05) Estimate

Benzinga Earnings
·
May 15

BRIEF-Celcuity Q1 Adjusted EPS USD -0.86 Vs. IBES Estimate USD -1.05

Reuters
·
May 15

Celcuity Q1 EPS USD -0.97

THOMSON REUTERS
·
May 15

Celcuity Inc: Expect Cash, Cash Equivalents, Investments & Drawdowns on Debt Facility to Finance Operations Through 2027

THOMSON REUTERS
·
May 15

Analysts Are Bullish on Top Healthcare Stocks: Celcuity (CELC), Rubicon Organics (ROMJF)

TIPRANKS
·
May 15

Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib

TIPRANKS
·
May 14

Stock Track | Celcuity Soars 5.04% Intraday on FDA Priority Review and Expanded Phase 3 Trial for Breast Cancer Drug

Stock Track
·
May 14

Celcuity Expands Gedatolisib Phase 3 Program in First-Line Breast Cancer Setting

MT Newswires Live
·
May 14

Celcuity Inc - FDA Grants Priority Review to Celcuity's Nda for Gedatolisib With Pdufa Date July 17, 2026

THOMSON REUTERS
·
May 14

Celcuity Inc - Submits Patent Application for Subcutaneous Formulation of Gedatolisib

THOMSON REUTERS
·
May 14

Celcuity Inc - Holds Type B Meeting With FDA on Amended Phase 3 Trial Design

THOMSON REUTERS
·
May 14

Celcuity’s Phase 3 Viktoria-2 Trial of Gedatolisib as a First-Line Treatment for Hr+/Her2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

THOMSON REUTERS
·
May 14

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 13

Celcuity Inc expected to post a loss of $1.05 a share - Earnings Preview

Reuters
·
May 13